ENHANCE-D:在牙科诊疗环境中比较强化戒烟干预与极简建议对成人吸烟者影响的实用性三臂随机对照试验方案
ENHANCE-D是一项在NHS牙科环境中开展的多中心、实用性、三臂、平行组、个体随机对照优效性试验,纳入1215名当前规律吸烟的成人患者,按1:2:2随机分配至极简建议(VBA)、标准疗程尼古丁替代疗法(NRT)或电子烟 starter kit 三组。主要结局为6个月时经生化验证的戒烟率,关键次要结局为牙周炎亚组6个月时探诊深度(PPD)≥5 mm的牙周位点百分比。
要点
- ENHANCE-D试验纳入1215名成人吸烟者,按1:2:2随机分配至VBA、NRT或电子烟 starter kit 三组。
- 主要结局为6个月时经生化验证的戒烟率。
- 牙周炎亚组关键次要结局为6个月时PPD≥5 mm的牙周位点百分比。
核心结论
- 该试验旨在确认强化戒烟支持能否提高戒烟率、改善口腔健康并具有良好成本效益。
研究设计与样本
- 多中心、实用性、三臂、平行组、个体随机对照优效性试验,包含内部预试验,在NHS牙科环境中开展,共纳入1215名当前规律吸烟的成人患者。
- 参与者按1:2:2随机分配至极简建议(VBA)组、标准疗程尼古丁替代疗法(NRT)组或电子烟 starter kit 组。
- 牙周炎亚组患者接受额外口腔检查并采集样本。
主要发现
- 主要结局为6个月时经生化验证的戒烟率。
- 关键次要结局为牙周炎亚组6个月时探诊深度(PPD)≥5 mm的牙周位点百分比。
- 参与者对试验目的设盲,不了解治疗分组;牙周健康结局由经过培训且校准的评估者记录,评估者对干预分组设盲。
- 参与者招募于2022年7月开始,内部预试验于2023年5月进入主试验。
- 将开展定性过程评估,探索参与者接受研究干预的体验,以及牙科团队、NHS委托方、服务管理者和政策制定者的观点;经济评估包括成本效果分析和成本效益分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Smoking is a key contributor to health inequalities, particularly impacting oral health. Periodontal (gum) health is significantly affected by smoking. With their extensive reach, regular and frequent patient contact, and potential teachable moments, dental teams are well placed to support patients to stop smoking. This is currently mainly provided through Very Brief Advice (VBA) interventions and so there is scope to enhance the cessation support offered. A large definitive trial is needed to confirm whether this would lead to improved smoking quit rates, improved oral health, and be good value for money. METHODS: The ENHANCE-D trial is a multi-centre, pragmatic, definitive, 3-arm, parallel group, individually randomised controlled superiority trial, including an internal pilot, conducted in NHS dental settings. In total, 1215 patients who are current regular smokers will be randomly allocated using a 1:2:2 ratio to the following: (i) VBA; (ii) the offer of a standard course of Nicotine Replacement Therapy (NRT); (iii) or the offer of an e-cigarette starter kit. A subgroup of patients with periodontitis (gum disease) will have additional oral examinations and samples collected. The primary outcome is biochemically verified smoking abstinence at 6 months. A key secondary outcome is the percentage of periodontal sites with probing pocket depths (PPDs) ≥ 5 mm at 6 months in the periodontitis subgroup. Participants will be blinded to the purpose of the trial and not be aware of the treatment packages. Periodontal health outcomes will be recorded by trained and aligned assessors, blinded to intervention arm. Participant recruitment started in July 2022 with an internal pilot progressing to the main trial in May 2023. A qualitative process evaluation will explore participants' experiences of receiving the study interventions, alongside the views of dental teams, NHS commissioners, service managers, and policymakers. An economic evaluation will include a cost-effectiveness analysis and a cost-benefit analysis. DISCUSSION: This will be the largest contemporary randomised trial of smoking cessation interventions in dental settings and one of the first to evaluate enhanced interventions. E-cigarettes were included as an intervention due to growing evidence of their effectiveness. They will be compared to VBA and NRT, and oral health outcomes assessed. The multi-centre, pragmatic design of this trial supports the external validity and potential for impacting clinical practice. TRIAL REGISTRATION: ISRCTN 13158982. Registered on 10 May 2022. https://www.isrctn.com/ISRCTNISRCTN13158982.
引用
- Holliday R, Wilson N, Ryan V, et al. ENHANCE-D: protocol for a pragmatic, 3-arm, randomised controlled trial comparing the impact of enhanced smoking cessation interventions to very brief advice for adult smokers in dental care settings. Trials. 2025. PMID: 40722041. doi:10.1186/s13063-025-08954-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。